ERBB2 and breast cancer: Using luminal-HER2+ BC cells, Lesniak et al. [93] reported that the spontaneous conversion of trastuzumab-responsive luminal/HER2+ cells to a trastuzumab-refractory CD44+/CD24−/low phenotype through EMT was accompanied by a strong down-regulation of HER2.